Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Baricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Manoharan, Sivananthan, Ying, Lee Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346539/
https://www.ncbi.nlm.nih.gov/pubmed/35938147
http://dx.doi.org/10.1155/2022/8332819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346539/
https://www.ncbi.nlm.nih.gov/pubmed/35938147
http://dx.doi.org/10.1155/2022/8332819

Ejemplares similares